A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

Lu Si; Xiaoshi Zhang; Yongqian Shu; Hongming Pan; Di Wu; Jiwei Liu; Fang Lou; Lili Mao; Xuan Wang; Xizhi Wen; Yanhong Gu; Lingjun Zhu; Shijie Lan; Xin Cai; Scott J. Diede; Yu Zhou; Jun Ge; Jianfeng Li; Haiyan Wu; Jun Guo

doi:10.1016/j.tranon.2019.02.007

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Pembrolizumab was well tolerated and provided clinically meaningful antitumor activity as second-line therapy in Chinese patients with advanced melanoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Si et al. (2019) studied this question.

synapsesocial.com/papers/69e5b80cbde0d10efc13c504 https://doi.org/10.1016/j.tranon.2019.02.007

View Full Paper

Ask AI

Bookmark

Share

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

Ask about this paper

Abstract

Discussion

Cite This Study

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading